Screener
4D Molecular Therapeutics FDMT Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 64,980 | 40,699 |
| General and administrative | 11,687 | 12,936 |
| Total operating expenses | 76,667 | 53,635 |
| Loss from operations | (73,620) | (53,621) |
| Other income (expense): | ||
| Interest income | 4,864 | 5,582 |
| Other income (expense), net | (4) | 67 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's total operating expenses?
- 4D Molecular Therapeutics (FDMT) reported total operating expenses of $76.67M in Q1 2026.
- How has 4D Molecular Therapeutics's total operating expenses changed year-over-year?
- 4D Molecular Therapeutics's total operating expenses increased by 42.9% year-over-year, from $53.64M to $76.67M.
- What is the long-term trend for 4D Molecular Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's total operating expenses has grown at a 28.6% compound annual growth rate (CAGR), from $89.37M to $244.76M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about 4D Molecular Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude